-
1
-
-
80052028124
-
Treatment of allergic asthma: Modulation of Th2 cells and their responses
-
Bosnjak B, Stelzmueller B, Erb KJ, et al. Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res. 2011;12:114-30.
-
(2011)
Respir Res
, vol.12
, pp. 114-130
-
-
Bosnjak, B.1
Stelzmueller, B.2
Erb, K.J.3
-
2
-
-
84873389433
-
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
-
Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330-8.
-
(2013)
Eur Respir J
, vol.41
, pp. 330-338
-
-
Piper, E.1
Brightling, C.2
Niven, R.3
-
3
-
-
84908095090
-
Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
-
Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134:769-79.
-
(2014)
J Allergy Clin Immunol
, vol.134
, pp. 769-779
-
-
Leung, D.Y.1
Guttman-Yassky, E.2
-
4
-
-
84901826411
-
Advances in the diagnosis and therapeutic management of atopic dermatitis
-
Vestergaard C, Deleuran M. Advances in the diagnosis and therapeutic management of atopic dermatitis. Drugs. 2014;74:757-69.
-
(2014)
Drugs
, vol.74
, pp. 757-769
-
-
Vestergaard, C.1
Deleuran, M.2
-
5
-
-
84918564629
-
Therapeutic strategies in extrinsic atopic dermatitis: Focus on inhibition of IL-4 as a new pharmacological approach
-
Di Lernia V. Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach. Expert Opin Ther Targets. 2015;19:87-96.
-
(2015)
Expert Opin Ther Targets
, vol.19
, pp. 87-96
-
-
Di Lernia, V.1
-
6
-
-
79951966004
-
Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life
-
Guilbert TW, Garris C, Jhingran P, et al. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma. 2011;48:126-32.
-
(2011)
J Asthma
, vol.48
, pp. 126-132
-
-
Guilbert, T.W.1
Garris, C.2
Jhingran, P.3
-
7
-
-
84922352134
-
The translational revolution and use of biologics in patients with inflammatory skin diseases
-
Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135:324-36.
-
(2015)
J Allergy Clin Immunol
, vol.135
, pp. 324-336
-
-
Noda, S.1
Krueger, J.G.2
Guttman-Yassky, E.3
-
8
-
-
84865085421
-
Guidelines for treatment of atopic eczema (atopic dermatitis) Part II
-
Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venerol. 2012;26:1176-93.
-
(2012)
J Eur Acad Dermatol Venerol
, vol.26
, pp. 1176-1193
-
-
Ring, J.1
Alomar, A.2
Bieber, T.3
-
9
-
-
84879401471
-
Dupilumab in persistent asthma with elevated eosinophil levels
-
Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455-66.
-
(2013)
N Engl J Med
, vol.368
, pp. 2455-2466
-
-
Wenzel, S.1
Ford, L.2
Pearlman, D.3
-
10
-
-
0032522641
-
An antagonistic IL-4 mutant prevents type I allergy in the mouse: Inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo
-
Grunewald SM, Werthmann A, Schnarr B, et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol. 1998;160:4004-9.
-
(1998)
J Immunol
, vol.160
, pp. 4004-4009
-
-
Grunewald, S.M.1
Werthmann, A.2
Schnarr, B.3
-
11
-
-
0037841660
-
Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma
-
Hahn C, Teufel M, Herz U, et al. Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Immunol. 2003;111:1361-9.
-
(2003)
J Allergy Clin Immunol
, vol.111
, pp. 1361-1369
-
-
Hahn, C.1
Teufel, M.2
Herz, U.3
-
12
-
-
84939937146
-
New pathogenic and therapeutic paradigms in atopic dermatitis
-
Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73:311-18.
-
(2015)
Cytokine
, vol.73
, pp. 311-318
-
-
Malajian, D.1
Guttman-Yassky, E.2
-
13
-
-
49549108250
-
Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation
-
Howell MD, Fairchild HR, Kim BE, et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol. 2008;128:2248-58.
-
(2008)
J Invest Dermatol
, vol.128
, pp. 2248-2258
-
-
Howell, M.D.1
Fairchild, H.R.2
Kim, B.E.3
-
14
-
-
84873333462
-
The multifunctional role of filaggrin in allergic skin disease
-
McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131:280-91.
-
(2013)
J Allergy Clin Immunol
, vol.131
, pp. 280-291
-
-
McAleer, M.A.1
Irvine, A.D.2
-
15
-
-
80053517839
-
Filaggrin mutations associated with skin and allergic diseases
-
Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315-27.
-
(2011)
N Engl J Med
, vol.365
, pp. 1315-1327
-
-
Irvine, A.D.1
McLean, W.H.2
Leung, D.Y.3
-
16
-
-
16844386596
-
Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis
-
Hatano Y, Terashi H, Arakawa S, et al. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol. 2005;124:786-92.
-
(2005)
J Invest Dermatol
, vol.124
, pp. 786-792
-
-
Hatano, Y.1
Terashi, H.2
Arakawa, S.3
-
17
-
-
84903269864
-
The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products
-
Meckfessel MH, Brandt S. The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products. J Am Acad Dermatol. 2014;71:177-84.
-
(2014)
J Am Acad Dermatol
, vol.71
, pp. 177-184
-
-
Meckfessel, M.H.1
Brandt, S.2
-
19
-
-
77951890216
-
IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation
-
Sehra S, Yao Y, Howell MD, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010;184:3186-90.
-
(2010)
J Immunol
, vol.184
, pp. 3186-3190
-
-
Sehra, S.1
Yao, Y.2
Howell, M.D.3
-
20
-
-
3242798310
-
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
-
Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752-60.
-
(2004)
Nat Immunol
, vol.5
, pp. 752-760
-
-
Dillon, S.R.1
Sprecher, C.2
Hammond, A.3
-
21
-
-
84857054959
-
IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis
-
Bao L, Shi VY, Chan LS. IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis. Mol Immunol. 2012;50:91-7.
-
(2012)
Mol Immunol
, vol.50
, pp. 91-97
-
-
Bao, L.1
Shi, V.Y.2
Chan, L.S.3
-
22
-
-
84906255127
-
Biologic therapy in asthma: Entering the new age of personalized medicine
-
Fajt ML, Wenzel SE. Biologic therapy in asthma: entering the new age of personalized medicine. J Asthma. 2014;51:669-76.
-
(2014)
J Asthma
, vol.51
, pp. 669-676
-
-
Fajt, M.L.1
Wenzel, S.E.2
-
23
-
-
80054117099
-
Association of polymorphisms in genes encoding IL-4, IL-13 and their receptors with atopic dermatitis in a Korean population
-
Namkung JH, Lee JE, Kim E, et al. Association of polymorphisms in genes encoding IL-4, IL-13 and their receptors with atopic dermatitis in a Korean population. Exp Dermatol. 2011;20:915-9.
-
(2011)
Exp Dermatol
, vol.20
, pp. 915-919
-
-
Namkung, J.H.1
Lee, J.E.2
Kim, E.3
-
24
-
-
0034973569
-
Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer
-
Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Gen. 2001;69:138-47.
-
(2001)
Am J Hum Gen
, vol.69
, pp. 138-147
-
-
Ritchie, M.D.1
Hahn, L.W.2
Roodi, N.3
-
25
-
-
4143122127
-
Gene-gene interaction between interleukin- 4 and interleukin-4 receptor alpha in Korean children with asthma
-
Lee SG, Kim BS, Kim JH, et al. Gene-gene interaction between interleukin- 4 and interleukin-4 receptor alpha in Korean children with asthma. Clin Exp Allergy. 2004;34:1202-8.
-
(2004)
Clin Exp Allergy
, vol.34
, pp. 1202-1208
-
-
Lee, S.G.1
Kim, B.S.2
Kim, J.H.3
-
26
-
-
77649198441
-
Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma
-
Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev. 2010;19:46-54.
-
(2010)
Eur Respir Rev
, vol.19
, pp. 46-54
-
-
Oh, C.K.1
Geba, G.P.2
Molfino, N.3
-
27
-
-
0029876629
-
Stat6 is required for mediating responses to IL-4 and for development of Th2 cells
-
Kaplan MH, Schindler U, Smiley ST, et al. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4:313-9.
-
(1996)
Immunity
, vol.4
, pp. 313-319
-
-
Kaplan, M.H.1
Schindler, U.2
Smiley, S.T.3
-
28
-
-
30044449492
-
IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis
-
Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12:99-106.
-
(2006)
Nat Med
, vol.12
, pp. 99-106
-
-
Fichtner-Feigl, S.1
Strober, W.2
Kawakami, K.3
-
29
-
-
4344607622
-
Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma
-
Lee GR, Flavell RA. Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol. 2004;16:1155-60.
-
(2004)
Int Immunol
, vol.16
, pp. 1155-1160
-
-
Lee, G.R.1
Flavell, R.A.2
-
30
-
-
52049123606
-
Enhanced CCL26 production by IL-4 through IFN-gamma-induced upregulation of type 1 IL-4 receptor in keratinocytes
-
Nishi N, Yamamoto S, Ou W, et al. Enhanced CCL26 production by IL-4 through IFN-gamma-induced upregulation of type 1 IL-4 receptor in keratinocytes. Biochem Biophys Res Commun. 2008;376:234-40.
-
(2008)
Biochem Biophys Res Commun
, vol.376
, pp. 234-240
-
-
Nishi, N.1
Yamamoto, S.2
Ou, W.3
-
31
-
-
48349104562
-
Correlation of IL-31 serum levels with severity of atopic dermatitis
-
Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol. 2008;122:421-3.
-
(2008)
J Allergy Clin Immunol
, vol.122
, pp. 421-423
-
-
Raap, U.1
Wichmann, K.2
Bruder, M.3
-
32
-
-
59949089656
-
Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling
-
Zheng T, Oh MH, Oh SY, et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129:742-51.
-
(2009)
J Invest Dermatol
, vol.129
, pp. 742-751
-
-
Zheng, T.1
Oh, M.H.2
Oh, S.Y.3
-
33
-
-
10744227480
-
A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse model of asthma
-
Nishikubo K, Murata Y, Tamaki S, et al. A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse model of asthma. Gene Ther. 2003;10:2119-25.
-
(2003)
Gene Ther
, vol.10
, pp. 2119-2125
-
-
Nishikubo, K.1
Murata, Y.2
Tamaki, S.3
-
34
-
-
0035340763
-
A murine IL-4 receptor antagonist that inhibits IL-4- And IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness
-
Tomkinson A, Duez C, Cieslewicz G, et al. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol. 2001;166:5792-800.
-
(2001)
J Immunol
, vol.166
, pp. 5792-5800
-
-
Tomkinson, A.1
Duez, C.2
Cieslewicz, G.3
-
35
-
-
34247522910
-
IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys
-
Bree A, Schlerman FJ, Wadanoli M, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007;119:1251-7.
-
(2007)
J Allergy Clin Immunol
, vol.119
, pp. 1251-1257
-
-
Bree, A.1
Schlerman, F.J.2
Wadanoli, M.3
-
36
-
-
48049089594
-
YM-341619 suppresses the differentiation of spleen T cells into Th2 cells in vitro, eosinophilia, and airway hyperresponsiveness in rat allergic models
-
Ohga K, Kuromitsu S, Takezawa R, et al. YM-341619 suppresses the differentiation of spleen T cells into Th2 cells in vitro, eosinophilia, and airway hyperresponsiveness in rat allergic models. Eur J Pharmacol. 2008;590:409-16.
-
(2008)
Eur J Pharmacol
, vol.590
, pp. 409-416
-
-
Ohga, K.1
Kuromitsu, S.2
Takezawa, R.3
-
37
-
-
0031019987
-
A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction
-
Grunewald SM, Kunzmann S, Schnarr B, et al. A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction. J Biol Chem. 1997;272:1480-3.
-
(1997)
J Biol Chem
, vol.272
, pp. 1480-1483
-
-
Grunewald, S.M.1
Kunzmann, S.2
Schnarr, B.3
-
38
-
-
77957764848
-
IL-4 receptor alpha polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist
-
Slager RE, Hawkins GA, Ampleford EJ, et al. IL-4 receptor alpha polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. J Allergy Clin Immunol. 2010;126:875-8.
-
(2010)
J Allergy Clin Immunol
, vol.126
, pp. 875-878
-
-
Slager, R.E.1
Hawkins, G.A.2
Ampleford, E.J.3
-
39
-
-
0034995872
-
Efficacy of soluble IL-4 receptor for the treatment of adults with asthma
-
Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001;107:963-70.
-
(2001)
J Allergy Clin Immunol
, vol.107
, pp. 963-970
-
-
Borish, L.C.1
Nelson, H.S.2
Corren, J.3
-
40
-
-
0036379740
-
Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma
-
Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130:93-100.
-
(2002)
Clin Exp Immunol
, vol.130
, pp. 93-100
-
-
Hart, T.K.1
Blackburn, M.N.2
Brigham-Burke, M.3
-
41
-
-
80053084755
-
Lebrikizumab treatment in adults with asthma
-
Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-98.
-
(2011)
N Engl J Med
, vol.365
, pp. 1088-1098
-
-
Corren, J.1
Lemanske, R.F.2
Hanania, N.A.3
-
42
-
-
84897379012
-
Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial
-
De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133:989-96.
-
(2014)
J Allergy Clin Immunol
, vol.133
, pp. 989-996
-
-
De Boever, E.H.1
Ashman, C.2
Cahn, A.P.3
-
43
-
-
69549129344
-
Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma
-
Burmeister Getz E, Fisher DM, Fuller R. Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol. 2009;49:1025-36.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 1025-1036
-
-
Burmeister Getz, E.1
Fisher, D.M.2
Fuller, R.3
-
44
-
-
77953039047
-
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma
-
Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181:788-96.
-
(2010)
Am J Respir Crit Care Med
, vol.181
, pp. 788-796
-
-
Corren, J.1
Busse, W.2
Meltzer, E.O.3
-
45
-
-
84903887689
-
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis
-
Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130-9.
-
(2014)
N Engl J Med
, vol.371
, pp. 130-139
-
-
Beck, L.A.1
Thaci, D.2
Hamilton, J.D.3
-
46
-
-
84879352861
-
Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma
-
Wechsler ME. Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. N Engl J Med. 2013;368:2511-3.
-
(2013)
N Engl J Med
, vol.368
, pp. 2511-2513
-
-
Wechsler, M.E.1
-
47
-
-
84864445917
-
IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist
-
Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol. 2012;130:516-22e4.
-
(2012)
J Allergy Clin Immunol
, vol.130
-
-
Slager, R.E.1
Otulana, B.A.2
Hawkins, G.A.3
-
48
-
-
0027451432
-
Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation
-
Kruse N, Shen BJ, Arnold S, et al. Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation. EMBO J. 1993;12:5121-9.
-
(1993)
EMBO J
, vol.12
, pp. 5121-5129
-
-
Kruse, N.1
Shen, B.J.2
Arnold, S.3
-
49
-
-
0027435159
-
An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: Support for a common component shared by IL-4 and IL-13 receptors
-
Aversa G, Punnonen J, Cocks BG, et al. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. J Exp Med. 1993;178:2213-8.
-
(1993)
J Exp Med
, vol.178
, pp. 2213-2218
-
-
Aversa, G.1
Punnonen, J.2
Cocks, B.G.3
-
50
-
-
0030950732
-
IL-4 receptor complexes containing or lacking the gamma C chain are inhibited by an overlapping set of antagonistic IL-4 mutant proteins
-
Schnarr B, Ezernieks J, Sebald W, et al. IL-4 receptor complexes containing or lacking the gamma C chain are inhibited by an overlapping set of antagonistic IL-4 mutant proteins. Int Immunol. 1997;9:861-8.
-
(1997)
Int Immunol
, vol.9
, pp. 861-868
-
-
Schnarr, B.1
Ezernieks, J.2
Sebald, W.3
-
51
-
-
66149140228
-
IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis
-
Morioka T, Yamanaka K, Mori H, et al. IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis. Brit J Dermatol. 2009;160:1172-9.
-
(2009)
Brit J Dermatol
, vol.160
, pp. 1172-1179
-
-
Morioka, T.1
Yamanaka, K.2
Mori, H.3
-
52
-
-
84876472759
-
Mutant interleukin-4/13 signaling blockade successfully suppresses acute phase inflammation
-
Nakanishi T, Yamanaka K, Kakeda M, et al. Mutant interleukin-4/13 signaling blockade successfully suppresses acute phase inflammation. Arch Dermatol Res. 2013;305:241-7.
-
(2013)
Arch Dermatol Res
, vol.305
, pp. 241-247
-
-
Nakanishi, T.1
Yamanaka, K.2
Kakeda, M.3
-
53
-
-
85029086430
-
Safety and efficacy of dupilumab versus placebo for moderate-to-severe atopic dermatitis in patients using topical corticosteroids (TCS): Greater efficacy observed with concomitant therapy compared to TCS alone
-
3 March San Diego CA
-
Thaci D, Worm M, Ren H, et al. Safety and efficacy of dupilumab versus placebo for moderate-to-severe atopic dermatitis in patients using topical corticosteroids (TCS): Greater efficacy observed with concomitant therapy compared to TCS alone. Presented at: Annual Meeting, American Academy of Allergy, Asthma, and Immunology; 3 March 2014; San Diego, CA.
-
(2014)
Annual Meeting, American Academy of Allergy, Asthma, and Immunology
-
-
Thaci, D.1
Worm, M.2
Ren, H.3
-
54
-
-
85029116278
-
Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A 12-week, Randomized, Double-Blind, Placebo-Controlled Study
-
4 March San Diego CA
-
Bieber TRM. Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A 12-week, Randomized, Double-Blind, Placebo-Controlled Study. Presented at: Annual Meeting, American Academy of Allergy, Asthma, and Immunology; 4 March 2014; San Diego, CA.
-
(2014)
Annual Meeting, American Academy of Allergy, Asthma, and Immunology
-
-
Bieber, T.R.M.1
-
55
-
-
84919635394
-
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
-
Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293-300.
-
(2014)
J Allergy Clin Immunol
, vol.134
, pp. 1293-1300
-
-
Hamilton, J.D.1
Suarez-Farinas, M.2
Dhingra, N.3
-
56
-
-
84922387096
-
Targeted therapy for allergic diseases: At the intersection of cutting-edge science and clinical practice
-
Boguniewicz M, Leung DY. Targeted therapy for allergic diseases: at the intersection of cutting-edge science and clinical practice. J Allergy Clin Immunol. 2015;135:354-6.
-
(2015)
J Allergy Clin Immunol
, vol.135
, pp. 354-356
-
-
Boguniewicz, M.1
Leung, D.Y.2
-
57
-
-
35348909044
-
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies
-
Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370:1422-31.
-
(2007)
Lancet
, vol.370
, pp. 1422-1431
-
-
Wenzel, S.1
Wilbraham, D.2
Fuller, R.3
|